<?xml version='1.0' encoding='utf8'?>
<text id="AMALGUM_academic_cytobiology" title="Cytobiology of Human Prostate Cancer Cells and Its Clinical Applications" shortTitle="cytobiology" author="Kenichiro Ishii" type="academic" dateCollected="2019-11-03" sourceURL="https://www.mdpi.com/2077-0383/8/10/1716/htm" speakerList="none" speakerCount="0">
<p>
<s type="decl">
The	DT	the
number	NN	number
of	IN	of
males	NNS	male
diagnosed	VBN	diagnose
with	IN	with
prostate	NN	prostate
cancer	NN	cancer
(	-LRB-	(
PCa	NNP	PCa
)	-RRB-	)
is	VBZ	be
increasing	VBG	increase
all	RB	all
over	IN	over
the	DT	the
world	NN	world
.	.	.
</s>
<s type="sub">
Most	JJS	most
patients	NNS	patient
with	IN	with
early-stage	JJ	early-stage
PCa	NN	PCa
can	MD	can
be	VB	be
treated	VBN	treat
by	IN	by
the	DT	the
appropriate	JJ	appropriate
therapy	NN	therapy
,	,	,
such	JJ	such
as	IN	as
radical	JJ	radical
prostatectomy	NN	prostatectomy
or	CC	or
irradiation	NN	irradiation
.	.	.
</s>
<s type="decl">
On	IN	on
the	DT	the
other	JJ	other
hand	NN	hand
,	,	,
androgen	NN	androgen
deprivation	NN	deprivation
therapy	NN	therapy
(	-LRB-	(
ADT	NNP	ADT
)	-RRB-	)
is	VBZ	be
the	DT	the
standard	JJ	standard
systemic	JJ	systemic
therapy	NN	therapy
given	VBN	give
to	IN	to
patients	NNS	patient
with	IN	with
advanced	JJ	advanced
PCa	NNP	PCa
.	.	.
</s>
<s type="decl">
ADT	NNP	ADT
induces	VBZ	induce
temporary	JJ	temporary
remission	NN	remission
,	,	,
but	CC	but
the	DT	the
majority	NN	majority
of	IN	of
patients	NNS	patient
(	-LRB-	(
approximately	RB	approximately
60	CD	60
%	NN	%
)	-RRB-	)
eventually	RB	eventually
progress	VBP	progress
to	IN	to
castration-resistant	JJ	castration-resistant
prostate	NN	prostate
cancer	NN	cancer
(	-LRB-	(
CRPC	NNP	CRPC
)	-RRB-	)
,	,	,
which	WDT	which
is	VBZ	be
associated	VBN	associate
with	IN	with
a	DT	a
high	JJ	high
mortality	NN	mortality
rate	NN	rate
.	.	.
</s>
</p>
<p>
<s type="decl">
Generally	RB	generally
,	,	,
well-differentiated	JJ	well-differentiated
PCa	NN	PCa
cells	NNS	cell
are	VBP	be
androgen-dependent	JJ	androgen-dependent
,	,	,
i.e.	FW	i.e.
,	,	,
androgen	NN	androgen
receptor	NN	receptor
(	-LRB-	(
AR	NN	AR
)	-RRB-	)
signaling	NN	signaling
regulates	VBZ	regulate
cell	NN	cell
cycle	NN	cycle
and	CC	and
differentiation	NN	differentiation
.	.	.
</s>
<s type="decl">
Loss	NN	loss
of	IN	of
AR	NN	AR
signaling	NN	signaling
after	IN	after
ADT	NNP	ADT
triggers	VBZ	trigger
androgen-independent	JJ	androgen-independent
outgrowth	NN	outgrowth
,	,	,
generating	VBG	generate
poorly	RB	poorly
differentiated	VBN	differentiate
,	,	,
uncontrollable	JJ	uncontrollable
PCa	NN	PCa
cells	NNS	cell
.	.	.
</s>
<s type="decl">
Once	IN	once
PCa	NNP	PCa
cells	NNS	cell
lose	VBP	lose
their	PRP$	their
sensitivity	NN	sensitivity
to	IN	to
ADT	NNP	ADT
,	,	,
effective	JJ	effective
therapies	NNS	therapy
are	VBP	be
limited	VBN	limit
.	.	.
</s>
<s type="decl">
In	IN	in
the	DT	the
last	JJ	last
few	JJ	few
years	NNS	year
,	,	,
however	RB	however
,	,	,
several	JJ	several
new	JJ	new
options	NNS	option
for	IN	for
the	DT	the
treatment	NN	treatment
of	IN	of
CRPC	NNP	CRPC
have	VBP	have
been	VBN	be
approved	VBN	approve
,	,	,
e.g.	FW	e.g.
,	,	,
the	DT	the
CYP17	NNP	CYP17
inhibitor	NN	inhibitor
,	,	,
the	DT	the
AR	NNP	AR
antagonist	NN	antagonist
,	,	,
and	CC	and
the	DT	the
taxane	NN	taxane
.	.	.
</s>
<s type="decl">
Despite	IN	despite
this	DT	this
progress	NN	progress
in	IN	in
the	DT	the
development	NN	development
of	IN	of
new	JJ	new
drugs	NNS	drug
,	,	,
there	EX	there
is	VBZ	be
a	DT	a
high	JJ	high
medical	JJ	medical
need	NN	need
for	IN	for
optimizing	VBG	optimize
the	DT	the
sequence	NN	sequence
and	CC	and
combination	NN	combination
of	IN	of
approved	VBN	approve
drugs	NNS	drug
.	.	.
</s>
<s type="sub">
Thus	RB	thus
,	,	,
identification	NN	identification
of	IN	of
predictive	JJ	predictive
biomarkers	NNS	biomarker
may	MD	may
help	VB	help
in	IN	in
the	DT	the
context	NN	context
of	IN	of
personalized	JJ	personalized
medicine	NN	medicine
to	TO	to
guide	VB	guide
treatment	NN	treatment
decisions	NNS	decision
,	,	,
improve	VB	improve
clinical	JJ	clinical
outcomes	NNS	outcome
,	,	,
and	CC	and
prevent	VB	prevent
unnecessary	JJ	unnecessary
side	NN	side
effects	NNS	effect
.	.	.
</s>
</p>
<p>
<s type="decl">
Departments	NNS	department
of	IN	of
Nephro-Urologic	NNP	Nephro-Urologic
Surgery	NNP	Surgery
and	CC	and
Andrology	NNP	Andrology
(	-LRB-	(
Professor	NNP	Professor
Emeritus	NNP	Emeritus
Yoshiki	NNP	Yoshiki
Sugimura	NNP	Sugimura
)	-RRB-	)
and	CC	and
Oncologic	NNP	Oncologic
Pathology	NNP	Pathology
(	-LRB-	(
Professor	NNP	Professor
Emeritus	NNP	Emeritus
Taizo	NNP	Taizo
Shiraishi	NNP	Shiraishi
)	-RRB-	)
,	,	,
Mie	NNP	Mie
University	NNP	University
Graduate	NNP	Graduate
School	NNP	School
of	IN	of
Medicine	NNP	Medicine
,	,	,
organized	VBD	organize
the	DT	the
semi-closed	JJ	semi-closed
symposium	NN	symposium
on	IN	on
Biology	NNP	biology
of	IN	of
Prostate	NNP	Prostate
Gland	NNP	Gland
Ise-Shima	NNP	Ise-Shima
.	.	.
</s>
<s type="decl">
This	DT	this
symposium	NN	symposium
was	VBD	be
started	VBN	start
in	IN	in
<date when="2002">
2002	CD	2002
</date>
and	CC	and
was	VBD	be
held	VBN	hold
every	DT	every
four	CD	4
years	NNS	year
in	IN	in
<date when="2006">
2006	CD	2006
</date>
,	,	,
<date when="2010">
2010	CD	2010
</date>
,	,	,
<date when="2014">
2014	CD	2014
</date>
,	,	,
and	CC	and
<date when="2018">
2018	CD	2018
</date>
without	IN	without
any	DT	any
financial	JJ	financial
support	NN	support
from	IN	from
pharmaceutical	JJ	pharmaceutical
companies	NNS	company
and	CC	and
chemical	NN	chemical
industries	NNS	industry
.	.	.
</s>
<s type="decl">
Each	DT	each
year	NN	year
,	,	,
the	DT	the
symposium	NN	symposium
was	VBD	be
attended	VBN	attend
by	IN	by
40	CD	40
â€“	SYM	-
50	CD	50
Japanese	JJ	Japanese
investigators	NNS	investigator
with	IN	with
expertise	NN	expertise
and	CC	and
interest	NN	interest
in	IN	in
biology	NN	biology
of	IN	of
the	DT	the
prostate	NN	prostate
gland	NN	gland
and	CC	and
PCa	NNP	PCa
.	.	.
</s>
<s type="decl">
The	DT	the
goal	NN	goal
of	IN	of
this	DT	this
symposium	NN	symposium
was	VBD	be
to	TO	to
discuss	VB	discuss
the	DT	the
biological	JJ	biological
mechanism	NN	mechanism
of	IN	of
the	DT	the
development	NN	development
and	CC	and
progression	NN	progression
of	IN	of
prostatic	JJ	prostatic
proliferative	JJ	proliferative
diseases	NNS	disease
such	JJ	such
as	IN	as
benign	JJ	benign
prostatic	JJ	prostatic
hyperplasia	NN	hyperplasia
(	-LRB-	(
BPH	NNP	BPH
)	-RRB-	)
and	CC	and
PCa	NNP	PCa
.	.	.
</s>
<s type="decl">
Several	JJ	several
major	JJ	major
topic	NN	topic
areas	NNS	area
were	VBD	be
discussed	VBN	discuss
,	,	,
e.g.	FW	e.g.
,	,	,
the	DT	the
pathophysiology	NN	pathophysiology
of	IN	of
BPH	NNP	BPH
,	,	,
the	DT	the
tumor	NN	tumor
microenvironment	NN	microenvironment
of	IN	of
PCa	NNP	PCa
,	,	,
AR	NNP	AR
signaling	NN	signaling
in	IN	in
PCa	NN	PCa
progression	NN	progression
,	,	,
and	CC	and
the	DT	the
development	NN	development
of	IN	of
PCa	NN	PCa
detection	NN	detection
and	CC	and
diagnosis	NN	diagnosis
.	.	.
</s>
<s type="decl">
This	DT	this
Special	NNP	Special
Issue	NNP	Issue
includes	VBZ	include
the	DT	the
major	JJ	major
topics	NNS	topic
discussed	VBN	discuss
at	IN	at
the	DT	the
symposium	NN	symposium
in	IN	in
<date when="2018">
2018	CD	2018
</date>
.	.	.
</s>
</p>
<p>
<s type="decl">
In	IN	in
this	DT	this
Special	NNP	Special
Issue	NNP	Issue
,	,	,
we	PRP	we
focused	VBD	focus
on	IN	on
cytobiology	NN	cytobiology
of	IN	of
human	JJ	human
PCa	NN	PCa
cells	NNS	cell
and	CC	and
its	PRP$	its
clinical	JJ	clinical
applications	NNS	application
to	TO	to
develop	VB	develop
a	DT	a
major	JJ	major
step	NN	step
towards	IN	towards
personalized	JJ	personalized
medicine	NN	medicine
matched	VBN	match
to	IN	to
the	DT	the
individual	JJ	individual
needs	NNS	need
of	IN	of
patients	NNS	patient
with	IN	with
early-stage	JJ	early-stage
and	CC	and
advanced	JJ	advanced
PCa	NN	PCa
and	CC	and
CRPC	NNP	CRPC
.	.	.
</s>
<s type="decl">
We	PRP	we
hope	VBP	hope
that	IN	that
this	DT	this
Special	JJ	Special
Issue	NNP	Issue
attracts	VBZ	attract
a	DT	a
lot	NN	lot
of	IN	of
attention	NN	attention
for	IN	for
readers	NNS	reader
with	IN	with
expertise	NN	expertise
and	CC	and
interest	NN	interest
in	IN	in
the	DT	the
cytobiology	NN	cytobiology
of	IN	of
human	JJ	human
PCa	NN	PCa
cells	NNS	cell
and	CC	and
its	PRP$	its
clinical	JJ	clinical
applications	NNS	application
.	.	.
</s>
</p>
</text>